Cargando…
Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
STUDY OBJECTIVES: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111–200 pg/mL) a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113791/ https://www.ncbi.nlm.nih.gov/pubmed/35554594 http://dx.doi.org/10.1093/sleep/zsac052 |
_version_ | 1784709645767540736 |
---|---|
author | van der Hoeven, Adrienne Elisabeth Fronczek, Rolf Schinkelshoek, Mink Sebastian Roelandse, Frederik Willem Cornelis Bakker, Jaap Adriaan Overeem, Sebastiaan Bijlenga, Denise Lammers, Gert Jan |
author_facet | van der Hoeven, Adrienne Elisabeth Fronczek, Rolf Schinkelshoek, Mink Sebastian Roelandse, Frederik Willem Cornelis Bakker, Jaap Adriaan Overeem, Sebastiaan Bijlenga, Denise Lammers, Gert Jan |
author_sort | van der Hoeven, Adrienne Elisabeth |
collection | PubMed |
description | STUDY OBJECTIVES: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111–200 pg/mL) and the diagnostic value of cataplexy characteristics in individuals with central disorders of hypersomnolence. METHODS: Retrospective cross-sectional study of 355 people with known CSF hypocretin-1 levels who visited specialized Sleep-Wake Centers in the Netherlands. For n = 271, we had full data on cataplexy type (“typical” or “atypical” cataplexy). RESULTS: Compared to those with normal hypocretin-1 levels (>200 pg/mL), a higher percentage of individuals with intermediate hypocretin-1 levels had typical cataplexy (75% or 12/16 vs 9% or 8/88, p < .05), and/or met the diagnostic polysomnographic (PSG) and Multiple Sleep Latency Test (MSLT) criteria for narcolepsy (50 vs 6%, p < .001). Of those with typical cataplexy, 88% had low, 7% intermediate, and 5% normal hypocretin-1 levels (p < .001). Atypical cataplexy was also associated with hypocretin deficiency but to a lesser extent. A hypocretin-1 cutoff of 150 pg/mL best predicted the presence of typical cataplexy and/or positive PSG and MSLT findings. CONCLUSION: Individuals with intermediate hypocretin-1 levels or typical cataplexy more often have outcomes fitting the PSG and MSLT criteria for narcolepsy than those with normal levels or atypical cataplexy. In addition, typical cataplexy has a much stronger association with hypocretin-1 deficiency than atypical cataplexy. We suggest increasing the NT1 diagnostic hypocretin-1 cutoff and adding the presence of clearly defined typical cataplexy to the diagnostic criteria of NT1. Clinical trial information: This study is not registered in a clinical trial register, as it has a retrospective database design. |
format | Online Article Text |
id | pubmed-9113791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91137912022-05-18 Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 van der Hoeven, Adrienne Elisabeth Fronczek, Rolf Schinkelshoek, Mink Sebastian Roelandse, Frederik Willem Cornelis Bakker, Jaap Adriaan Overeem, Sebastiaan Bijlenga, Denise Lammers, Gert Jan Sleep Neurological Disorders STUDY OBJECTIVES: The diagnosis of narcolepsy type 1 (NT1) is based upon the presence of cataplexy and/or a cerebrospinal fluid (CSF) hypocretin-1/orexin-A level ≤ 110 pg/mL. We determined the clinical and diagnostic characteristics of patients with intermediate hypocretin-1 levels (111–200 pg/mL) and the diagnostic value of cataplexy characteristics in individuals with central disorders of hypersomnolence. METHODS: Retrospective cross-sectional study of 355 people with known CSF hypocretin-1 levels who visited specialized Sleep-Wake Centers in the Netherlands. For n = 271, we had full data on cataplexy type (“typical” or “atypical” cataplexy). RESULTS: Compared to those with normal hypocretin-1 levels (>200 pg/mL), a higher percentage of individuals with intermediate hypocretin-1 levels had typical cataplexy (75% or 12/16 vs 9% or 8/88, p < .05), and/or met the diagnostic polysomnographic (PSG) and Multiple Sleep Latency Test (MSLT) criteria for narcolepsy (50 vs 6%, p < .001). Of those with typical cataplexy, 88% had low, 7% intermediate, and 5% normal hypocretin-1 levels (p < .001). Atypical cataplexy was also associated with hypocretin deficiency but to a lesser extent. A hypocretin-1 cutoff of 150 pg/mL best predicted the presence of typical cataplexy and/or positive PSG and MSLT findings. CONCLUSION: Individuals with intermediate hypocretin-1 levels or typical cataplexy more often have outcomes fitting the PSG and MSLT criteria for narcolepsy than those with normal levels or atypical cataplexy. In addition, typical cataplexy has a much stronger association with hypocretin-1 deficiency than atypical cataplexy. We suggest increasing the NT1 diagnostic hypocretin-1 cutoff and adding the presence of clearly defined typical cataplexy to the diagnostic criteria of NT1. Clinical trial information: This study is not registered in a clinical trial register, as it has a retrospective database design. Oxford University Press 2022-03-07 /pmc/articles/PMC9113791/ /pubmed/35554594 http://dx.doi.org/10.1093/sleep/zsac052 Text en © Sleep Research Society 2022. Published by Oxford University Press on behalf of the Sleep Research Society. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neurological Disorders van der Hoeven, Adrienne Elisabeth Fronczek, Rolf Schinkelshoek, Mink Sebastian Roelandse, Frederik Willem Cornelis Bakker, Jaap Adriaan Overeem, Sebastiaan Bijlenga, Denise Lammers, Gert Jan Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
title | Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
title_full | Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
title_fullStr | Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
title_full_unstemmed | Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
title_short | Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
title_sort | intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1 |
topic | Neurological Disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113791/ https://www.ncbi.nlm.nih.gov/pubmed/35554594 http://dx.doi.org/10.1093/sleep/zsac052 |
work_keys_str_mv | AT vanderhoevenadrienneelisabeth intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT fronczekrolf intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT schinkelshoekminksebastian intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT roelandsefrederikwillemcornelis intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT bakkerjaapadriaan intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT overeemsebastiaan intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT bijlengadenise intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 AT lammersgertjan intermediatehypocretin1cerebrospinalfluidlevelsandtypicalcataplexytheirsignificanceinthediagnosisofnarcolepsytype1 |